PierianDx company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

pieriandx.com

Total Raised

$88.3M

Investors Count

10

Deal Terms

2

PierianDx Funding, PierianDx Valuation & PierianDx Revenue

6 Fundings

PierianDx's latest funding round was a Series B - II for $30M on November 2, 2021.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

11/2/2021

Series B - II

$30M

0

FY undefined

11

11/2/2021

Loan - II

$99M

0

FY undefined

10

4/15/2020

Loan

$99M

0

FY undefined

0

10/28/2019

Series B

$99M

0

FY undefined

10

2/12/2018

Series A - II

$99M

0

FY undefined

10

Date

11/2/2021

11/2/2021

4/15/2020

10/28/2019

2/12/2018

Round

Series B - II

Loan - II

Loan

Series B

Series A - II

Amount

$30M

$99M

$99M

$99M

$99M

Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

11

10

0

10

10

PierianDx Deal Terms

2 Deal Terms

PierianDx's deal structure is available for 2 funding rounds, including their Series A - II from February 12, 2018.

Round

Series A - II

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A - II

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

PierianDx Investors

10 Investors

PierianDx has 10 investors. Inova Health Systems invested in PierianDx's Series B - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/7/2016

11/2/2021

3
Series A, Series B (2019), Series B - II (2021)

Corporation

Virginia

1/7/2016

11/2/2021

3
Series A, Series B (2019), Series B - II (2021)

Venture Capital

New York

10/28/2019

11/2/2021

2
Series B, Series B - II (2021)

Venture Capital

New York

00/00/0000

00/00/0000

SJF Ventures

Subscribe to see more

Venture Capital

North Carolina

00/00/0000

00/00/0000

OrbiMed Advisors

Subscribe to see more

Venture Capital

New York

First funding

1/7/2016

1/7/2016

10/28/2019

00/00/0000

00/00/0000

Last Funding

11/2/2021

11/2/2021

11/2/2021

00/00/0000

00/00/0000

Investor

SJF Ventures

OrbiMed Advisors

Rounds

3
Series A, Series B (2019), Series B - II (2021)
3
Series A, Series B (2019), Series B - II (2021)
2
Series B, Series B - II (2021)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Venture Capital

Venture Capital

Venture Capital

Venture Capital

Location

Virginia

New York

New York

North Carolina

New York

PierianDx Acquisitions

1 Acquisition

PierianDx acquired 1 company. Their latest acquisition was Tute Genomics on October 12, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/12/2016

Other

$99M

$8.59M

Acquired

4

Date

10/12/2016

Investment Stage

Other

Companies

Valuation

$99M

Total Funding

$8.59M

Note

Acquired

Sources

4

You May Also Like

N
Navican Genomics

Navican provides a personalized approach to testing, diagnosing, and treating cancer. The company's unique process analyzes the genetic makeup of a patient's cancer and employs a team of skilled molecular tumor specialists to review each test and determine how to most effectively treat that cancer case.

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.

Fabric Genomics Logo
Fabric Genomics

Fabric Genomics, formerly Omicia, is a computational genomics company offering end-to-end genomic data analysis, annotation, curation, classification and reporting solutions to clinical labs, hospital labs, country sequencing programs and life science companies. Fabric Genomics' analytic capabilities begin with raw data analysis and include the delivery of rapid, comprehensive insights for high throughout panels, exomes, and whole genomes. The company can process any NGS file input (e.g. FASTQ, BAM or VCF) providing alignment, variant calling, annotation, guideline-driven variant classification, variant interpretation and clinical reporting for both hereditary disease and oncology. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics and molecular diagnostics, and is headquartered in Oakland, California with satellite offices in London, Seattle, Salt Lake City and Boston. By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics is leading the way in precision healthcare.

Gene42 Logo
Gene42

Gene42 is a medical technology and clinical software company that develops clinical software tools for collecting and analyzing phenotypic information for patients with genetic disorders and cancers. Their solution, PhenoTips, allows for efficient recording of patient data in a standardized format, which facilitates automated searches of annotated genes and disease databases (differential diagnosis), enables effortless querying and sharing of anonymized patient data by users and provides a user-friendly interface with advanced features that reduces clinician's workload and seamlessly integrates into clinical work flow. Gene42 provides support contracts and custom development for PhenoTips software. Data organization when it comes to patient care is critical, especially in rare diseases when certain symptoms or features of a disease might not be seen on a regular basis. In the age of "big data" and electronic health records, Gene42 is striving to make personalized medicine more effective for patients and their doctors.

Q
Q-State Biosciences

Q-State Biosciences is a precision medicine company creating new genetically targeted medicines for people living with nervous system disorders. The company's proprietary ResQueTM Platform incorporates a suite of technologies to map each patient’s unique genome to a genetic therapy that targets the root cause of disease.

Illumina Logo
Illumina

Illumina works to apply new technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic. The company was founded in 1998 and is based in San Diego, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.